Abstract
Quantitative MRI provides important information about tissue properties in brain both in normal ageing and in degenerative disorders. Although it is well known that those with Alzheimer’s disease (AD) show a specific pattern and faster rate of atrophy than controls, the precise spatial and temporal patterns of quantitative MRI in AD are unknown. We aimed to investigate neuroimaging correlates of AD using serial quantitative MRI. In our study, twenty-one subjects with AD and thirty-two similar-aged healthy controls underwent two serial MRI scans at baseline and 12 months. Tissue characteristics were captured using two quantitative MRI parameters: longitudinal relaxation time (qT1) and transverse relaxation time (qT2). The two groups (AD and controls) were statistically compared using a voxel based quantification (VBQ) method based on Matlab and SPM8. At baseline, subjects with AD showed a significant reduction of qT1 and qT2 compared to controls in bilateral temporal and parietal lobes, hippocampus, and basal ganglia. This pattern was also observed at follow-up. Longitudinally, in AD we found a significant increase rather than further reduction of qT1 and qT2 from the baseline in bilateral hippocampus, thalamus and right caudate nucleus. In addition, the longitudinal change of qT1 in left hippocampus was negatively correlated with cognitive decline in AD over the 1-year period, and the general disease severity significantly predicted the amount of increase of qT1 in bilateral hippocampus over 12 months. The longitudinal change of qT2 in left parahippocampus correlated with change in neuropsychiatric features over time. In summary, quantitative MRI parameters were reduced in AD cross-sectionally, but increased over time, showing distinct spatiotemporal patterns from the atrophy in AD. We also showed the clinical relevance of quantitative MRI parameters, indicating their potential promise as new imaging markers in AD.
Keywords: Alzheimer’s disease, amyloid, early diagnostics, relaxometry, uantitative MRI, VBQ.
Current Alzheimer Research
Title:Cortical and Subcortical Changes in Alzheimer’s Disease: A Longitudinal and Quantitative MRI Study
Volume: 13 Issue: 5
Author(s): Li Su, Andrew M. Blamire, Rosie Watson, Jiabao He, Benjamin Aribisala and John T. O’Brien
Affiliation:
Keywords: Alzheimer’s disease, amyloid, early diagnostics, relaxometry, uantitative MRI, VBQ.
Abstract: Quantitative MRI provides important information about tissue properties in brain both in normal ageing and in degenerative disorders. Although it is well known that those with Alzheimer’s disease (AD) show a specific pattern and faster rate of atrophy than controls, the precise spatial and temporal patterns of quantitative MRI in AD are unknown. We aimed to investigate neuroimaging correlates of AD using serial quantitative MRI. In our study, twenty-one subjects with AD and thirty-two similar-aged healthy controls underwent two serial MRI scans at baseline and 12 months. Tissue characteristics were captured using two quantitative MRI parameters: longitudinal relaxation time (qT1) and transverse relaxation time (qT2). The two groups (AD and controls) were statistically compared using a voxel based quantification (VBQ) method based on Matlab and SPM8. At baseline, subjects with AD showed a significant reduction of qT1 and qT2 compared to controls in bilateral temporal and parietal lobes, hippocampus, and basal ganglia. This pattern was also observed at follow-up. Longitudinally, in AD we found a significant increase rather than further reduction of qT1 and qT2 from the baseline in bilateral hippocampus, thalamus and right caudate nucleus. In addition, the longitudinal change of qT1 in left hippocampus was negatively correlated with cognitive decline in AD over the 1-year period, and the general disease severity significantly predicted the amount of increase of qT1 in bilateral hippocampus over 12 months. The longitudinal change of qT2 in left parahippocampus correlated with change in neuropsychiatric features over time. In summary, quantitative MRI parameters were reduced in AD cross-sectionally, but increased over time, showing distinct spatiotemporal patterns from the atrophy in AD. We also showed the clinical relevance of quantitative MRI parameters, indicating their potential promise as new imaging markers in AD.
Export Options
About this article
Cite this article as:
Su Li, Blamire M. Andrew, Watson Rosie, He Jiabao, Aribisala Benjamin and O’Brien T. John, Cortical and Subcortical Changes in Alzheimer’s Disease: A Longitudinal and Quantitative MRI Study, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116141416
DOI https://dx.doi.org/10.2174/1567205013666151116141416 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry How Does Pain Induce Negative Emotion? Role of the Bed Nucleus of the Stria Terminalis in Pain-Induced Place Aversion
Current Molecular Medicine Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Alzheimer's disease: Targeting the Cholinergic System
Current Neuropharmacology Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies
Current Alzheimer Research Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Current Topics in Medicinal Chemistry Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Perinatal Management of Fetal Tumors
Current Pediatric Reviews Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity?
Current Aging Science Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry The Sirtuin Inhibitor Nicotinamide Enhances Neuronal Cell Survival During Acute Anoxic Injury Through AKT, BAD, PARP, and Mitochondrial Associated "Anti-Apoptotic" Pathways
Current Neurovascular Research Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Dissecting the Diverse Actions of Pro- and Mature Neurotrophins
Current Alzheimer Research Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets